M
M. Degardin
Researcher at university of lille
Publications - 17
Citations - 2302
M. Degardin is an academic researcher from university of lille. The author has contributed to research in topics: Docetaxel & Cetuximab. The author has an hindex of 11, co-authored 17 publications receiving 2123 citations.
Papers
More filters
Journal ArticleDOI
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Jan B. Vermorken,Eva Remenar,Carla M.L. van Herpen,Thierry Gorlia,Ricard Mesia,M. Degardin,John S. Stewart,Svetislav Jelic,Jan Betka,Joachim H. Preiss,Danielle Van den Weyngaert,Ahmad Awada,Didier Cupissol,Heinz Roland Kienzer,Augustin Rey,Isabelle Desaunois,Jacques Bernier,Jean-Louis Lefebvre +17 more
TL;DR: Induction chemotherapy with the addition of docetaxel significantly improved progression-free and overall survival in patients with unresectable squamous-cell carcinoma of the head and neck.
Journal ArticleDOI
Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study
Jean-Louis Lefebvre,Yoann Pointreau,Frederic Rolland,Marc Alfonsi,Alain Baudoux,Christian Sire,Dominique De Raucourt,Olivier Malard,M. Degardin,C. Tuchais,Emmanuel Blot,Michel Rives,Emile Reyt,Jean Marc Tourani,Lionel Geoffrois,Frederic Peyrade,Francois Guichard,Dominique Chevalier,Emmanuel Babin,Philippe Lang,François Janot,Gilles Calais,Pascal Garaud,Etienne Bardet +23 more
TL;DR: There is no evidence that one treatment was superior to the other or could improve the outcome reported with ICT followed by RT alone, and the protocol that can best compare with RT alone after ICT is still to be determined.
Journal ArticleDOI
Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer.
Eric Lartigau,Emmanuelle Tresch,Juliette Thariat,Pierre Graff,Bernard Coche-Dequeant,Karen Benezery,Luis Schiappacasse,M. Degardin,Pierre-Yves Bondiau,Didier Peiffert,Jean-Louis Lefebvre,Thomas Lacornerie,Andrew Kramar +12 more
TL;DR: Short SBRT with cetuximab is an effective salvage treatment with good response rate in this poor prognosis population with previously irradiated HNC and this combination may be the reference treatment is this population.
Journal ArticleDOI
Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971)
Jan B. Vermorken,Éva Remenár,C.M.L. van Herpen,J. R. Germà Lluch,S. Stewart,Thierry Gorlia,M. Degardin,K. Schollen,Jacques Bernier +8 more
TL;DR: TPF (→RT) is superior to PF (→ RT) in terms of RR, PFS, OS and is better tolerated and after a median follow-up of 32 mo, TPF demonstrated significantly superior PFS.
Journal ArticleDOI
Salvage Stereotactic Reirradiation With or Without Cetuximab for Locally Recurrent Head-and-Neck Cancer: A Feasibility Study
B. Comet,Andrew Kramar,Mathieu Faivre-Pierret,Sylvain Dewas,Bernard Coche-Dequeant,M. Degardin,Jean-Louis Lefebvre,Thomas Lacornerie,Eric Lartigau +8 more
TL;DR: These results suggest that short SBRT with or without cetuximab is an effective salvage treatment with good response rate in this poor prognosis population with previously irradiated HNC.